Prof Ales Ryska talks to ecancer about the challenges and opportunities of incorporating KRAS as a novel biomarker.

He begins by explaining the importance of incorporating KRAS as a novel biomarker for lung cancer detection and treatment before considering what challenges and opportunities the use brings.

Prof Ryska then discusses what the current status of KRAS in precision medicine before considering whether KRAS incorporation will become standard in the future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.